Literature DB >> 7130704

Field trials of second-generation anticoagulants against difenacoum-resistant Norway rat populations.

J H Greaves, D S Shepherd, R Quy.   

Abstract

Trials of rodenticidal baits containing 50 p.p.m. difenacoum, 50 p.p.m. bromadiolone or 20 p.p.m. brodifacoum were carried out on farmsteads against populations of Rattus norvegicus containing difenacoum-resistant individuals. Six difenacoum treatments failed in 14--42 days of baiting. Two treatments with bromadiolone succeeded in 23 and 33 days, but four further treatments lasting 35--56 days failed to eradicate the populations. Brodifacoum gave virtually complete control of six populations in 21--73 days and of the ten residual populations left behind by the other two compounds, after baiting for a further 11--85 days. The performance of both bromadiolone and brodifacoum was well below that reported by previous investigators, indicating the possibility of low-grade resistance to these compounds in the difenacoum-resistant strain.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7130704      PMCID: PMC2134219          DOI: 10.1017/s0022172400070820

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  5 in total

1.  Field trials of bromadiolone against infestations of warfarin-resistant Rattus norvegicus.

Authors:  C G Richards
Journal:  J Hyg (Lond)       Date:  1981-06

2.  Field trials of WBA 8119 (PP 581, brodifacoum) against warfarin-resistant infestations of Rattus norvegicus.

Authors:  B D Rennison; A C Dubock
Journal:  J Hyg (Lond)       Date:  1978-02

3.  Laboratory evaluation of bromadiolone as a rodenticide for use against warfarin-resistant and non-resistant rats and mice.

Authors:  R Redfern; J E Gill
Journal:  J Hyg (Lond)       Date:  1980-04

4.  Laboratory evaluation of WBA 8119 as a rodenticide for use against warfarin-resistant and non-resistant rats and mice.

Authors:  R Redfern; J E Gill; M R Hadler
Journal:  J Hyg (Lond)       Date:  1976-12

5.  The detection of rodent resistance to anticoagulants.

Authors:  D C Drummond; B D Rennison
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

  5 in total
  7 in total

Review 1.  Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis.

Authors:  Martin J Shearer; Paul Newman
Journal:  J Lipid Res       Date:  2014-01-31       Impact factor: 5.922

2.  The genetic basis of resistance to anticoagulants in rodents.

Authors:  Hans-Joachim Pelz; Simone Rost; Mirja Hünerberg; Andreas Fregin; Ann-Charlotte Heiberg; Kristof Baert; Alan D MacNicoll; Colin V Prescott; Anne-Sophie Walker; Johannes Oldenburg; Clemens R Müller
Journal:  Genetics       Date:  2005-05-06       Impact factor: 4.562

3.  Consequences of the Y139F Vkorc1 mutation on resistance to AVKs: in-vivo investigation in a 7th generation of congenic Y139F strain of rats.

Authors:  Agnes Grandemange; Michael Hans Kohn; Romain Lasseur; Christiane Longin-Sauvageon; Philippe Berny; Etienne Benoit
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

4.  Field trials of a new sub-acute rodenticide flupropadine, against wild Norway rats (Rattus norvegicus).

Authors:  A P Buckle
Journal:  J Hyg (Lond)       Date:  1985-10

5.  An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management.

Authors:  J Davies; A Ingham
Journal:  Int J Pharm       Date:  2015-03-30       Impact factor: 5.875

6.  Efficacy of rodenticide baits with decreased concentrations of brodifacoum: Validation of the impact of the new EU anticoagulant regulation.

Authors:  Marcela Frankova; Vaclav Stejskal; Radek Aulicky
Journal:  Sci Rep       Date:  2019-11-14       Impact factor: 4.379

7.  Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling.

Authors:  Elisabeth Müller; Alexander Keller; Andreas Fregin; Clemens R Müller; Simone Rost
Journal:  BMC Genet       Date:  2014-02-04       Impact factor: 2.797

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.